电邮这篇文章 KORREKTsIYa DISLIPIDEMII V RAMKAKh VTORIChNOY PROFILAKTIKI IShEMIChESKOGO INSUL'TA: NOVYE TsELI TERAPII?
- 作者: Yanishevskiy SN1,2, Skiba Y.B1, Puchek VD3, Ryabtsev AY.1
-
隶属关系:
- ВМедА им. С.М. Кирова
- НМИЦ им. В.А. Алмазова
- Филиал №3 3 ЦВКГ им. А.А. Вишневского
- 期: 卷 38, 编号 3 (Прил) (2019)
- 页面: 183-184
- 栏目: Articles
- URL: https://journals.rcsi.science/RMMArep/article/view/26179
- DOI: https://doi.org/10.17816/rmmar26179
- ID: 26179
如何引用文章
全文:
详细
作者简介
S Yanishevskiy
ВМедА им. С.М. Кирова; НМИЦ им. В.А. АлмазоваСанкт-Петербург
Ya Skiba
ВМедА им. С.М. КироваСанкт-Петербург
V Puchek
Филиал №3 3 ЦВКГ им. А.А. ВишневскогоОдинцово
A Ryabtsev
ВМедА им. С.М. КироваСанкт-Петербург
参考
- Диагностика и коррекция нарушений липидного обмена с Целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. Российский кардиологический журнал №3 2017, с 5-22.
- ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. - https://doi.org/10.103/eurheartj/ehz455.
- Cannon, C.P. et al. Ezetimibe added to statin therapy after acute coronary syndromes // Engl. J. Med.- 2015. - № 372. - 2387-2397.
- Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials// Lancet. - 2010. - № 376 - 1670-1681.
- Cholesterol Treatment Trialists Collaboration: Fulcher J., O’Connell R., Voysey M., Emberson J, Blackwell L., Mihaylova B., Simes J., Collins R., Kirby A., Colhoun H., Braunwald E., La Rosa J., Pedersen T.R., Tonkin A., Davis B., Sleight P., Franzosi M.G., Baigent C., Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials// Lancet. - 2015. - № 385. - 1397-1405.
- Hsia J., MacFadyen J.G., Monyak J., Ridker P.M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol №50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)// J. Am. Coll. Cardiol. - 2011. - №57. - 1666-1675.
- McCormack T., Dent R., Blagden M. Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date// Int. J. Clin. Pract. - 2016. - № 70. - 886-897.
- Navarese E.P., Robinson J.G., Kowalewski M., Kolodziejczak M., Andreotti F., Bliden K., Tantry U., Kubica J., Raggi P., Gurbel P.A. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis// JAMA. - № 2018. - № 319. -1566-1579.
- Nicholls S.J., Puri R., Anderson T. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial// JAMA. - 2016. - №316. - 2373-2384.
- Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N., Wiviott S.D., Murphy S.A., Kuder J.F., Wang H., Liu T., Wasserman S.M. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease// N. Engl. J. Med. - 2017. - № 376. -1713-1722.
- Schwartz G.G., Steg P.G., Szarek M. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome// N. Engl. J. Med. - 2018. - № 379. - 2097-2107.
- Steinberg D., Witztum J.L. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels// Proc. Natl. Acad. Sci. - 2009. - № 106. - 9546-9547.
补充文件
